4.7 Article

The case for early identification and intervention of chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference

期刊

KIDNEY INTERNATIONAL
卷 99, 期 1, 页码 34-47

出版社

ELSEVIER SCIENCE INC
DOI: 10.1016/j.kint.2020.10.012

关键词

alburninuria; chronic kidney disease; cost-effectiveness; creatinine; cystatin; detection; kidney failure; glomerular filtration rate; health systems; interventions; proteinuria; risk models; risk stratification; screening

资金

  1. KDIGO
  2. Akebia Therapeutics
  3. AstraZeneca
  4. Bayer HealthCare
  5. Boehringer Ingelheim
  6. Cricket Health
  7. CVS Kidney Care
  8. Fresenius Medical Care
  9. Gentian
  10. Janssen
  11. Kyowa Kirin
  12. Mundipharma
  13. Reata
  14. Relypsa
  15. Tricida

向作者/读者索取更多资源

Chronic kidney disease (CKD) is a significant global burden associated with higher morbidity and mortality, especially among individuals with lower socioeconomic status. Despite the availability of guidelines for evaluating and managing early CKD, there is still a lack of consensus on prioritizing early identification and intervention for CKD without incentives or quality measures.
Chronic kidney disease (CKD) causes substantial global morbidity and increases cardiovascular and all-cause mortality. Unlike other chronic diseases with established strategies for screening, there has been no consensus on whether health systems and governments should prioritize early identification and intervention for CKD. Guidelines on evaluating and managing early CKD are available but have not been universally adopted in the absence of incentives or quality measures for prioritizing CKD care. The burden of CKD falls disproportionately upon persons with lower socioeconomic status, who have a higher prevalence of CKD, limited access to treatment, and poorer outcomes. Therefore, identifying and treating CKD at the earliest stages is an equity imperative. In 2019, Kidney Disease: Improving Global Outcomes (KDIGO) held a controversies conference entitled Early Identification and Intervention in CKD. Participants identified strategies for screening, risk stratification, and treatment for early CKD and the key health system and economic factors for implementing these processes. A consensus emerged that CKD screening coupled with risk stratification and treatment should be implemented immediately for high-risk persons and that this should ideally occur in primary or community care settings with tailoring to the local context.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据